Cargando…

Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials

Detalles Bibliográficos
Autores principales:	Blauvelt, A., Rosmarin, D., Bieber, T., Simpson, E.L., Bagel, J., Worm, M., Deleuran, M., Katoh, N., Kawashima, M., Shumel, B., Chen, Z., Rossi, A.B., Hultsch, T., Ardeleanu, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850039/ https://www.ncbi.nlm.nih.gov/pubmed/30719707 http://dx.doi.org/10.1111/bjd.17703

Ejemplares similares

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
por: Wollenberg, A., et al.
Publicado: (2019)

Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials
por: Katoh, N., et al.
Publicado: (2019)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2020)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials
por: Silverberg, J.I., et al.
Publicado: (2019)

IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis
por: Paller, A.S., et al.
Publicado: (2022)

The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2021)

Dupilumab for atopic dermatitis
Publicado: (2019)

Response to R. Waldman et al.: ‘Does IL‐4 inhibition play a role in dupilumab‐associated conjunctivitis?’
por: Ardeleanu, M., et al.
Publicado: (2020)

Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2022)

Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)
por: Bagel, Jerry, et al.
Publicado: (2022)

Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)

Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
por: Armstrong, April, et al.
Publicado: (2021)

Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial
por: Worm, Margitta, et al.
Publicado: (2019)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion
por: Thyssen, J.P., et al.
Publicado: (2019)

IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis
por: Callewaert, Chris, et al.
Publicado: (2019)

Conjunctivitis in dupilumab clinical trials
por: Akinlade, B., et al.
Publicado: (2019)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2019)

Alopecia areata after dupilumab for atopic dermatitis
por: Mitchell, Krystal, et al.
Publicado: (2018)

Conjunctivitis in patients with atopic dermatitis treated with dupilumab
por: Ferreira, Sandra, et al.
Publicado: (2020)

Onychodystrophy associated with dupilumab therapy for atopic dermatitis
por: Zubek, Amanda E., et al.
Publicado: (2020)

Improvement of atopic dermatitis and alopecia universalis with dupilumab
por: Alotaibi, Lama, et al.
Publicado: (2021)

Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients
por: Shan, Jinpeng, et al.
Publicado: (2022)

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
por: Hamilton, Jennifer D., et al.
Publicado: (2021)

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension
por: Cork, M.J., et al.
Publicado: (2019)

Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
por: Peterson, Danielle M., et al.
Publicado: (2021)

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
por: Yosipovitch, Gil, et al.
Publicado: (2021)

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
por: Simpson, Eric L., et al.
Publicado: (2019)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
por: WOLLENBERG, Andreas, et al.
Publicado: (2022)

Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older
por: Simpson, Eric L., et al.
Publicado: (2021)

The evaluation of dupilumab treatment response in atopic dermatitis patients
por: Askin, Ozge, et al.
Publicado: (2020)

Dupilumab for the treatment of alopecia areata in children with atopic dermatitis
por: Cho, Sung Kyung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ml519gv8v370jaf47kmr1vun2o